Aubagne

Sartorius Stedim Biotech closes acquisition of BIA Separations

Retrieved on: 
Monday, November 2, 2020
Sartorius AG, Aubagne, Sartorius, BIA Separations, Human activities, Industries

AUBAGNE, France, Nov. 2, 2020 /PRNewswire/ -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations.

Key Points: 
  • AUBAGNE, France, Nov. 2, 2020 /PRNewswire/ -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations.
  • "BIA's portfolio is highly complementary to Sartorius Stedim Biotech.
  • 25 million euros in 2020 at profit margins that will be accretive to the underlying EBITDA margin of the Sartorius Stedim Biotech Group.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.

Sartorius Stedim Biotech SA: Information on Document Availability

Retrieved on: 
Tuesday, July 21, 2020
Sartorius AG, Aubagne, Sartorius, Industries, Human activities, Companies

The report on the first half 2020 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:

Key Points: 
  • The report on the first half 2020 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:
    It contains the following information:
    Consolidated financial statements for the period ended June 30, 2020
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont

Retrieved on: 
Thursday, July 2, 2020
Sartorius AG, Aubagne, Companies, Industries

As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.

Key Points: 
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.
  • The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies.

Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.

Retrieved on: 
Wednesday, June 24, 2020
Sartorius AG, Aubagne, Companies, Industries, Organizations

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.

Key Points: 
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.

Retrieved on: 
Wednesday, June 24, 2020
Sartorius AG, Aubagne, Companies, Industries, Organizations

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.

Key Points: 
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Sartorius Stedim Biotech Closes Acquisition of Selected Assets of Danaher Life Sciences

Retrieved on: 
Thursday, April 30, 2020
Sartorius AG, Companies, Sartorius, Danaher Corporation, Aubagne, Humans

AUBAGNE, France, April 30, 2020 /PRNewswire/ -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of selected life science businesses of Danaher Corporation as part of a broader transaction between Danaher and Sartorius Group, SSB's major shareholder.

Key Points: 
  • AUBAGNE, France, April 30, 2020 /PRNewswire/ -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of selected life science businesses of Danaher Corporation as part of a broader transaction between Danaher and Sartorius Group, SSB's major shareholder.
  • "The acquisition of this portfolio is a further milestone for Sartorius Stedim Biotech.
  • We are very pleased to welcome approximately 100 new employees at Sartorius Stedim Biotech and to combine our expertise to become even more relevant together for our biopharma customers," said Dr. Joachim Kreuzburg, CEO of Sartorius Stedim Biotech.
  • The total purchase price of the transaction between Danaher and Sartorius Groupis 825million U.S.dollars of which about a third will be allocated to the businesses purchased by Sartorius Stedim Biotech.

European and U.S. Antitrust Authorities Clear Acquisition of Select Danaher Life Science Businesses by Sartorius Stedim Biotech

Retrieved on: 
Friday, March 20, 2020
Sartorius AG, Aubagne, Sartorius, Human activities

AUBAGNE, France, March 20, 2020 /PRNewswire/ -- On March 18 and March 19, 2020 respectively, the European Commission and the U.S. Federal Trade Commission cleared the proposed acquisition of select Danaher life science businesses by Sartorius, SSB's major shareholder.

Key Points: 
  • AUBAGNE, France, March 20, 2020 /PRNewswire/ -- On March 18 and March 19, 2020 respectively, the European Commission and the U.S. Federal Trade Commission cleared the proposed acquisition of select Danaher life science businesses by Sartorius, SSB's major shareholder.
  • The total purchase price is approximately 825 million U.S. dollars in cash of which about a third will be allocated to the businesses purchased by Sartorius Stedim Biotech.
  • This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.

Sartorius Stedim Biotech Postpones Annual Shareholders' Meeting

Retrieved on: 
Tuesday, March 17, 2020
Sartorius AG, Aubagne, Sartorius, Euronext, Human activities, Companies

AUBAGNE, France, March 17, 2020 /PRNewswire/ -- Sartorius Stedim Biotech S.A. will postpone its Annual General Shareholders' Meeting formerly scheduled for March 24, 2020, to a later date due to the coronavirus pandemic and the associated restrictions imposed on travel and meetings.

Key Points: 
  • AUBAGNE, France, March 17, 2020 /PRNewswire/ -- Sartorius Stedim Biotech S.A. will postpone its Annual General Shareholders' Meeting formerly scheduled for March 24, 2020, to a later date due to the coronavirus pandemic and the associated restrictions imposed on travel and meetings.
  • Sartorius Stedim Biotech will inform its shareholders and the public in a timely manner about its further planning.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.